Drug Profile
Research programme: anticancer antibodies - LifeArc/Organon
Latest Information Update: 30 Jun 2017
Price :
$50
*
At a glance
- Originator Organon
- Developer MRC Technology; Schering-Plough
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Jun 2017 MRC Technology is now called LifeArc
- 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
- 19 Nov 2007 Organon has been acquired by Schering-Plough